Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.175 USD | +0.60% | -6.43% | 0.00% |
04-22 | Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target | MT |
04-22 | Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target | MT |
Valuation
Fiscal Period: December | 2024 | 2025 | 2026 |
---|---|---|---|
Capitalization 1 | 202.9 | - | - |
Enterprise Value (EV) 1 | 172.2 | 166.7 | 101.8 |
P/E ratio | -2.72 x | -2.45 x | -2.34 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | -2.37 x | -1.53 x | -0.65 x |
EV / FCF | -3.19 x | -2.38 x | -1.14 x |
FCF Yield | -31.4% | -42% | -87.4% |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 22,253 | - | - |
Reference price 2 | 9.120 | 9.120 | 9.120 |
Announcement Date | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | - | - | - |
EBITDA 1 | - | -72.68 | -109 | -156.4 |
EBIT 1 | - | -73.72 | -99.89 | -126.8 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -71.95 | -93.82 | -110.6 |
Net income 1 | -49.43 | -68.13 | -94.64 | -123.5 |
Net margin | - | - | - | - |
EPS 2 | -2.080 | -3.353 | -3.720 | -3.890 |
Free Cash Flow 1 | - | -54 | -70 | -89 |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share 2 | - | - | - | - |
Announcement Date | 3/6/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - |
EBIT 1 | -16.88 | -17.25 | -18.9 | -19.91 | -22.3 | -22.9 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -15.43 | -17.45 | -18.7 | -19.55 | -21.1 | -22.65 |
Net income 1 | -15.43 | -16.87 | -18.03 | -18.8 | -21.1 | -22.65 |
Net margin | - | - | - | - | - | - |
EPS 2 | -12.27 | -0.7333 | -0.7733 | -0.7967 | -0.8900 | -1.000 |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 5/13/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | - | 30.7 | 36.3 | 101 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | - | -54 | -70 | -89 |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex 1 | - | 0.4 | 0.5 | 0.5 |
Capex / Sales | - | - | - | - |
Announcement Date | 3/6/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 203M | |
+14.00% | 118B | |
+13.41% | 106B | |
-1.95% | 24.28B | |
+0.79% | 21.96B | |
-9.03% | 18.16B | |
-42.12% | 16.37B | |
-17.41% | 15.56B | |
+4.89% | 13.63B | |
+31.06% | 12.27B |
- Stock Market
- Equities
- BOLD Stock
- Financials Boundless Bio, Inc.